Dr. Vivek Vishnudas oversees the development of experimental therapeutics from conception and drug discovery to IND filing and First-in-Human studies. Drug-discovery programs are based on the novel disease targets/phenotype identified with Interrogative Biology®. Dr. Vishnudas leads an interdisciplinary team of drug-discovery scientists, biochemists and DMPK scientists to understand target tractability & pharmacology. Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners and aims to scale up BPGbio’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology® technology, and inventor of early-stage drug discovery platforms. His breadth of operations covers scientific leadership, strategic R&D initiatives, and intellectual property strategies.

Prior to moving to industry, Dr. Vishnudas was a research fellow in the Senator Paul D. Wellstone Center for Excellence in Muscular Dystrophy/BBRI, where he completed his postdoctoral training. Through his graduate school (University of Vermont) and postdoctoral fellowship, Vivek received extensive training in the field of muscle physiology and skeletal muscle diseases. Vivek has more than 20 U.S. and international patent applications (granted and pending) that cover wide areas of metabolic disease, oncology, and neurological indications.
Dr. Vishnudas received a master’s degree in Biochemistry from the National Dairy Research Institute (NDRI, ICAR India) and a Ph.D. in Biology from the University of Vermont. He has authored more than 15 peer reviewed publications.